A61P 5/20
For decreasing, blocking or antagonising the activity of pth
Official title: for decreasing, blocking or antagonising the activity of PTH
A61P5/20 (For decreasing, blocking or antagonising the activity of pth) appears on 176 US grants and 263 published applications in this corpus.
Search patents in A61P- Granted patents
- 176
- Published applications
- 263
- Assignees
- 115
- Inventors
- 490
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 3 | 0 |
| 1999 | 4 | 0 |
| 2000 | 1 | 0 |
| 2001 | 5 | 4 |
| 2002 | 5 | 3 |
| 2003 | 3 | 9 |
| 2004 | 2 | 6 |
| 2005 | 5 | 8 |
| 2006 | 3 | 9 |
| 2007 | 5 | 16 |
| 2008 | 1 | 3 |
| 2009 | 4 | 15 |
| 2010 | 6 | 15 |
| 2011 | 5 | 14 |
| 2012 | 7 | 13 |
| 2013 | 16 | 21 |
| 2014 | 11 | 10 |
| 2015 | 9 | 7 |
| 2016 | 13 | 17 |
| 2017 | 13 | 17 |
| 2018 | 8 | 18 |
| 2019 | 19 | 16 |
| 2020 | 4 | 10 |
| 2021 | 5 | 6 |
| 2022 | 5 | 6 |
| 2023 | 7 | 6 |
| 2024 | 2 | 7 |
| 2025 | 2 | 3 |
| 2026 | 1 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for reducing parathyroid levels18 Aug 2026US 12,708,629 B2Eirgen Pharma Ltd.
- Stabilized modified release vitamin D formulation and method of administering same25 Nov 2025US 12,478,631 B2Eirgen Pharma Ltd.
- Pediatric dosage forms, methods of making and using7 Oct 2025US 12,433,842 B2Eirgen Pharma Ltd.
- Pediatric dosage forms, methods of making and using5 Nov 2024US 12,133,917 B2Eirgen Pharma Ltd.
- PTH compounds with low peak-to-trough ratios2 Jan 2024US 11,857,603 B2Ascendis Pharma Bone Diseases A/S
- Pharmaceutical compositions of polymeric micellar cinacalcet, and methods of preparation and use thereof16 Jul 2026US 2026/0199234 A1Hangzhou Shixi Pharmaceutical Technology Co., Ltd.
- PTH Treatment Regimen Comprising Two PTH Compounds30 Apr 2026US 2026/0115298 A1
- Stabilized modified release vitamin d formulation and method of administering same5 Feb 2026US 2026/0034148 A1Eirgen Pharma Ltd.
- Compounds and Their Use as PDE4 Activators1 Jan 2026US 2026/0001876 A1Mironid Limited
- Methods For Treating Alzheimer's Disease or Dementia Using A Calcilytic And A Calcimimetic20 Nov 2025US 2025/0352609 A1
Most cited
By later US patents
- ActRII receptor polypeptides, methods and compositions121US 7,709,605 B2Acceleron Pharma Inc. · 2010
- Calcium receptor-active compounds114US 6,211,244 B1NPS Pharmaceuticals, Inc. · 2001
- Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxypheny1]-1,4-dihydro-4-oxoquinoline-3-carboxamide108US 8,163,772 B2Vertex Pharmaceuticals Incorporated · 2012
- Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide89US 8,362,253 B2Vertex Pharmaceutical Incorporated · 2013
- Actriib-Fc polynucleotides, polypeptides, and compositions83US 8,252,900 B2Acceleron Pharma Inc. · 2012